右ヒラー腫瘍に二次的な耐火性血管嵐に対する心臓神経縮小術
Saer Abu-Alrub1, Allan Tronchi1, Antoine Boudias1
1Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.
JACC. Case reports
|September 5, 2025
まとめ
希少なシンコペの原因である血管内阻害反応は,ヒラ筋の質量を持つ患者で特定されました. 心臓神経縮小療法で 副鼻腔停止と再発性昏睡の治療が成功しました
科学分野:
- 心臓病科
- 神経科学
- 医療診断
背景:
- 血管回路の反応や 副鼻腔節の問題に起因するかもしれません
- 67歳の女性が 副鼻腔停止で失眠しました
研究 の 目的:
- ハイラー・マスの患者の 昏睡の原因を調査する
- 血管阻害性シンコープに対する心臓神経破壊療法の有効性を評価する.
主な方法:
- 血管阻害反応を特定するための遠隔測定記録の分析
- 心電図と電解質検査を含む診断評価
- 治療は心臓神経縮小療法です
主要な成果:
- 遠隔測定では 血管系阻害反応が ヒラー質量によって引き起こされたことが判明しました
- 患者は心臓神経縮小術後,昏睡や鼻腔の休止が再発しなかった.
結論:
- ハイラーマスの機械的な圧縮は 血管阻害性シンコープを誘発する
- この状態の選択された患者に kardioneuroablationはペースメーカーに有効な代替手段です.
関連する概念動画
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
159
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
159
Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
Cardiac Catheterization II: Right Heart Catheterization
160
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
160
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106


